Kancera AB today announced that Dr. Thomas Olin, CEO of Kancera, will present the company at the 2012 BIO International Convention taking place June 18-21 in Boston, USA.
Read MoreKancera announces that Professor Carl-Henrik Heldin has been elected to Kancera ́s Board at the company's annual general meeting May 28.
Read MoreJanuary 1 - March 31, 2012 All figures relate to the Kancera Group unless otherwise specified. The 2011 comparison figures for operating income and income after financial items were affected by the release of negative goodwill of SEK 7m...
Read MoreKancera's inhibitors of ROR1 show an effect on leukemia cells from patients for whom standard therapy is not currently working. Kancera's partner and co-founder Professor Håkan Mellstedt and his research group at the Karolinska University Hospital conducted the studies.
Read MoreKancera has, in collaboration with Professor Håkan Mellstedt's research group at the Karolinska Institute, developed antibodies that permit the development of a diagnostic tool to identify patient response to treatment using Kancera's ROR inhibitors.
Read MoreKancera AB (publ), Sweden, has demonstrated effect with their PFKFB3 inhibitors in cells from three different types of solid tumors. In addition to the previously reported enhancement on effects off cisplatin's effect ion gastric cancer cells, the company has...
Read MoreKancera presents the company and its projects at Cambridge Innovation Center in Boston (MA) USA on Friday April 27th, 2012. The overall topic of the seminar is "Lead Generation and Structure-Based Drug Design in Cancer Research".
Read MoreKancera announced today that American Society of Clinical Oncology has selected Kancera's ROR project for presentation at this year's major conference in Chicago on June 1-5, 2012.The scientific results will be presented by Professor Håkan Mellstedt in a paper...
Read MoreKancera today announced that its ROR inhibitor show effect in an advanced and challenging human pancreatic cancer model. In the model, the Kancera compounds show superior efficacy compared to gemcitabine, today's most commonly used treatment for pancreatic cancer. The...
Read MoreJanuary 1 - December 31, 2011 All figures relate to the Kancera Group unless otherwise specified. Kancera's acquisition of iNovacia AB was completed on February 17, 2011 and iNovacia AB's operations are therefore included in the financial statements with...
Read More